Efficiency of Innovative Methods of Treatment of Progressive Facial Neuropathy in Aplastic Anemia

Abstract: Progressive facial neuropathy is a rare but debilitating complication in patients with aplastic anemia, often resistant to standard therapies due to underlying immunosuppression and chronic inflammation. This study aimed to evaluate the clinical efficiency of innovative treatment methods—specifically low-frequency transcutaneous electrical nerve stimulation (TENS) combined with neuropeptide infusion therapy—in comparison with conventional treatment. A total of 34 patients with clinically confirmed progressive facial neuropathy in the setting of aplastic anemia were enrolled and divided into two groups. Group A received standard therapy, while Group B received additional TENS and intravenous plasma-derived neuropeptides. By week 6, Group B showed significantly greater improvement in facial nerve function (House-Brackmann score), pain relief (VAS and NTSS-6), and inflammatory markers (CRP, IL-6), along with better quality of life outcomes. The innovative treatment was welltolerated and led to faster and more complete nerve recovery. These findings support the integration of regenerative and neuromodulatory therapies into neurorehabilitation protocols for hematological patients.